Investors Cash In On Editas Medicine Inc.’s -4.75% Loss – Stocks Register
Home  »  Companies   »  Investors Cash In On Editas Medicine Inc.’s ...

Investors Cash In On Editas Medicine Inc.’s -4.75% Loss

Editas Medicine Inc. (NASDAQ:EDIT) price closed lower on Monday, September 13, dropping -4.75% below its previous close.

>> 7 Top Picks for the Post-Pandemic Economy <<

A look at the daily price movement shows that the last close reads $66.10, with intraday deals fluctuated between $62.60 and $67.3599. The company’s 5Y monthly beta was ticking 1.94. Taking into account the 52-week price action we note that the stock hit a 52-week high of $99.95 and 52-week low of $27.01. The stock subtracted -3.66% on its value in the past month.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Editas Medicine Inc., which has a market valuation of $4.19 billion, is expected to release its quarterly earnings report Nov 04, 2021 – Nov 09, 2021. Analysts tracking EDIT have forecast the quarterly EPS to shrink by -0.82 per share this quarter, while the same analysts predict the annual EPS to hit -$3.47 for the year 2021 and up to -$3.48 for 2022. In this case, analysts estimate an annual EPS growth of -75.30% for the year and -0.30% for the next year.

The average estimate suggests sales growth for the quarter will likely fall by -91.00% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $19.03 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -79.00% below that which the company brought in 2021.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 1 upward and no downward reviews. On the technical perspective front, indicators give EDIT a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.

The overview shows that EDIT’s price is at present -1.79% off the SMA20 and 16.25% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 52.52, with weekly volatility standing at 6.60%. The indicator jumps to 7.14% when calculated based on the past 30 days. Editas Medicine Inc. (NASDAQ:EDIT)’s beta value is holding at 1.91, while the average true range (ATR) indicator is currently reading 4.84.

Turning out attention to how the Editas Medicine Inc. stock has performed in comparison to its peers in the industry, here’s what we find: EDIT’s stock is -4.75% on the day and 109.94% in the past 12 months, while Molecular Templates Inc. (MTEM) traded -1.14% in the last session and was positioned -49.58% down on its price 12 months ago. Elsewhere in the market, the S&P 500 Index has rallied 0.23% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.76%.

An analysis of the Editas Medicine Inc. (NASDAQ:EDIT) stock in terms of its daily trading volume indicates that the 3-month average is 1.99 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

Current records show that the company has 67.88M in outstanding shares. The insiders’ percentage holdings are 0.10% of outstanding shares while the percentage share held by institutions stands at 74.80%. But the -10.20% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam